Please login to the form below

Not currently logged in
Email:
Password:

New global role for Shanahan at FD

Founder of Santé Communications, Liz Shanahan, has been appointed global head of healthcare and life sciences for medical communications firm FD

Founder of Santé Communications, Liz Shanahan, has been appointed global head of healthcare and life sciences for medical communications firm FD.

Shanahan will lead FD's team of cross-practice experts who serve healthcare and life sciences clients across the company's global network. She will work with the regional heads and the heads of FD's healthcare and life sciences sector teams building from a base of about 50 specialist consultants worldwide.

Her focus will be on leveraging new opportunities across the group and developing FD's health and life science's offering in new markets and identifying ways of adding value for existing clients.

Shanahan founded Santé Communications in 1995 and her company joined FD four years ago as FD Santé.

Liz Shanahan
Liz Shanahan

Commething on her appointment, Shanahan said: "This is a tremendous opportunity and an exciting challenge. In the past 10 years the healthcare and pharmaceutical sector has become increasingly globalised. While the US and the EU remain dominant we see, for example, increasing activity in the Asia Pacific region.

"Across the world, the industry operates within many different national constraints but globally it shares the challenges of increasing pressure on medicine and technology access, escalating R&D costs with reduced output and ever increasing regulatory pressures. Dozens of pharmaceutical companies and healthcare providers, large and small already trust FD with their most important products on communication."

18th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics